TD001 for men with PSMA-positive metastatic prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new drug, TD001, in men whose prostate cancer has spread and is no longer responding to standard hormone therapy. It aims to see if TD001 is safe and effective against tumors that show a specific marker called PSMA.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your prostate cancer has spread to other parts of your body and is growing despite hormone therapy.
- You have at least one tumor that can be measured on a scan.
- Your organs (like kidneys, liver, and bone marrow) are working well enough.
- You have had orchiectomy (removal of testicles) or are on ongoing hormone-blocking therapy.
- You have already tried at least one newer hormone-blocking drug (like enzalutamide or abiraterone).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests a small-molecule treatment that carries radioactive material to help treat prostate cancer that has spread and keeps growing despite standard hormone-blocking treatment. It’s mainly looking to find a safe dose and see how well the approach works in people with limited treatment options.
This early-stage trial tests a new drug called TRC003 for men with advanced prostate cancer that has spread and stopped responding to standard treatments. The drug is designed to target cancer cells that show a specific marker called PSMA.
This Phase 1/2 trial tests a PSMA-targeted radioligand treatment (a drug that delivers radiation to prostate cancer cells) in men with metastatic castration-resistant prostate cancer that has gotten worse despite standard hormone therapies. It’s designed to see how the treatment works and whether it can help shrink or control cancer, while also studying safety and dosing.
This trial tests a new treatment that targets a protein called PSMA found on prostate cancer cells. It uses a radioactive form of the treatment to try to kill cancer cells while limiting damage to healthy cells. This study is for men with advanced prostate cancer that has stopped responding to other treatments.
This study tests a new experimental treatment for advanced prostate cancer that has spread and no longer responds to standard hormone therapy. The treatment is a radioactive drug that targets a protein called PSMA on cancer cells, aiming to deliver radiation directly to the tumor.
This trial tests a new radioactive drug designed to target and destroy prostate cancer cells. It is for men whose cancer has continued to grow despite hormone therapy and other treatments like enzalutamide or abiraterone.
Hear when a new Metastatic Castration-Resistant Prostatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.